A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation
contribute to the progression of the eye disease, age-related macular degeneration (AMD),
which is the leading cause of irreversible, severe loss of vision in people 55 years of age
and older in the developed world. TG100801 is a new drug that inhibits ocular angiogenesis,
vascular leak, and inflammation in laboratory studies, and may have great utility in the
treatment of diseases such as AMD.
The purpose of this study is to assess the safety, ocular tolerability, and blood
pharmacokinetics of TG100801 at escalating doses in healthy volunteers.